Gemcitabine hydrochloride is under clinical development by Fujifilm and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gemcitabine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gemcitabine hydrochloride overview

Gemcitabine hydrochloride (FF-10832) is under development for the treatment of advanced solid tumors including renal cell carcinoma, biliary tract cancer, urothelial cell cancer, non-small cell lung cancer. The drug candidate is a liposomal gemcitabine formulation administered through intravenous route. It acts by targeting ribonucleoside diphosphate reductase subunit M1. It is developed based on nano-dispersion technology.

It was also under development for the treatment of solid tumors including pancreatic cancer, bladder cancer and breast cancer. 

Fujifilm overview

Fujifilm designs, manufactures, and markets healthcare solutions, material solutions, and imaging systems. The company offers document solutions such as office products, office printers, allied production services and global services. Its major products include colour films, colour paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. Fujifilm also offers equipment and materials for medical systems, pharmaceuticals, cosmetics, and supplements. The company serves individual consumers and business enterprises. It has business presence across the Americas, Europe, Africa, Oceanic and Asia-Pacific. Fujifilm is headquartered in Minato-Ku, Tokyo, Japan.

For a complete picture of Gemcitabine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.